PB1790: ABCB1 AS A POTENTIAL BENEFICIAL TARGET OF MIDOSTAURIN IN ACUTE MYELOID LEUKEMIA

PB1790: ABCB1 AS A POTENTIAL BENEFICIAL TARGET OF MIDOSTAURIN IN ACUTE MYELOID LEUKEMIA

Bibliographic Details
Main Authors:	S. Sucha, A. Sorf, M. Svoren, D. Vagiannis, F. Ahmed, B. Visek, M. Ceckova
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000850012.85946.26

Similar Items

Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors
by: Ales Sorf, et al.
Published: (2020-06-01)

Midostaurin: an emerging treatment for acute myeloid leukemia patients
by: Gallogly MM, et al.
Published: (2016-04-01)

Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia
by: Lindsey T. Brinton, et al.
Published: (2020-06-01)

Experience with FLT3 Inhibitor Midostaurin in Newly Diagnosed Acute Myeloid Leukemia Patients
by: Mehmet Baysal, et al.
Published: (2021-03-01)

Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia
by: Andoni Garitano-Trojaola, et al.
Published: (2021-06-01)

Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom
by: Gabriel Tremblay, et al.
Published: (2018-10-01)

Isavuconazole therapy of disseminated and encephalic Saprochaete capitata infection in an acute myeloid leukemia patient treated with midostaurin.
by: Salvatore Perrone, et al.
Published: (2020-04-01)

PB1790: LOOKING ‘BENEATH’ THE SURFACE: PROTEOMICS AND GLYCIPROTEOMICS REVEAL NOVEL TARGETS FOR CAR-T CELL THERAPIES IN ACUTE MYELOID LEUKEMIA (AML)
by: Josephine Brysting, et al.
Published: (2023-08-01)

PB1829: ARGENTINEAN REAL WORLD EXPERIENCE ON MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY VS INTENSIVE CHEMOTHERAPY TO TREAT FLT3 POSITIVE ACUTE MYELOID LEUKEMIA PATIENTS
by: A. Navickas, et al.
Published: (2022-06-01)

Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study
by: Thomas Boyer, et al.
Published: (2019-09-01)

Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3
by: Hao Lu, et al.
Published: (2022-07-01)

MIDOSTAURIN ADDED TO CYTOSINE ARABINOSIDE PLUS IDARUBICIN (“7+3”) IN NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA
by: P Barreto, et al.
Published: (2021-10-01)

Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study
by: Pierantonio Menna, et al.
Published: (2023-10-01)

PB1890: TRIAL IN PROGRESS: A PHASE II STUDY OF MIDOSTAURIN COMBINED WITH INDUCTION/CONSOLIDATION CHEMOTHERAPY AND AS SINGLE-AGENT MAINTENANCE IN PEDIATRIC PATENTS WITH FLT3-MUTATED ACUTE MYELOID LEUKEMIA
by: Dirk Reinhardt, et al.
Published: (2023-08-01)

Post‐stem cell transplant maintenance in FLT3mut acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib
by: Karam Ashouri, et al.
Published: (2024-04-01)

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
by: Alexander E. Perl, et al.
Published: (2022-05-01)

Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia
by: Raquel C. Maia, et al.
Published: (2018-01-01)

P571: ORAL AZACITIDINE VS MIDOSTAURIN AS MAINTENANCE TREATMENT FOR FLT3 MUTANT ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION: AN INDIRECT TREATMENT COMPARISON
by: E. N. Oliva, et al.
Published: (2022-06-01)

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
by: Zheng Li, et al.
Published: (2022-02-01)

PB1795: BIO-INSPIRED NANOMEDICINE FOR TARGETED ACUTE MYELOID LEUKEMIA IMMUNOTHERAPY
by: X. Wang, et al.
Published: (2022-06-01)

P586: POTENTIAL DRUG-DRUG INTERACTIONS OF ANTIFUNGAL PROPHYLAXIS AND MIDOSTAURIN IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA – CLINICAL IMPLICATIONS OF THERAPEUTIC DRUG MONITORING
by: Carolin Joisten, et al.
Published: (2023-08-01)

Combined effect of midostaurin and sphingosine kinase-1 inhibitor on FMS-like tyrosine kinase 3 (FLT3) wild type acute myeloid leukemia cells
by: Şahin Hande Nur, et al.
Published: (2022-02-01)

European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis
by: Yang Yu, et al.
Published: (2019-11-01)

Molecular targeting in acute myeloid leukemia
by: Seah H. Lim, et al.
Published: (2017-08-01)

P514: V-FAST MASTER TRIAL: PRELIMINARY RESULTS OF TREATMENT WITH CPX-351 PLUS MIDOSTAURIN IN ADULTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA
by: J. McCloskey, et al.
Published: (2022-06-01)

Wnt/β-catenin pathway regulates <it>ABCB1</it> transcription in chronic myeloid leukemia
by: Corrêa Stephany, et al.
Published: (2012-07-01)

PB1832: ARTERIAL THROMBOSIS AND ACUTE MYELOID LEUKEMIA – IS THERE A CONNECTION?
by: N. Pantic, et al.
Published: (2022-06-01)

PB1832: INFLAMMATION INDUCED COAGULATION IN ACUTE MYELOID LEUKEMIA
by: Olivera Mitrović Ajtić, et al.
Published: (2023-08-01)

PB1782: INTEGRATIVE MOLECULAR SUBTYPES OF ACUTE MYELOID LEUKEMIA
by: Qianxing Mo, et al.
Published: (2023-08-01)

PB1847: ACUTE MYELOID LEUKEMIA – IS IT MORE BESIDES GENETIC ABNORMALITIES?
by: M. Urbano, et al.
Published: (2022-06-01)

Targeting neurolysin in acute myeloid leukemia
by: Sara Mirali, et al.
Published: (2020-07-01)

S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN
by: Frank G Rücker, et al.
Published: (2023-08-01)

PB1823: SECONDARY ACUTE MYELOID LEUKEMIA AND DE NOVO ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES DISTINCT LANDSCAPE, OR THE SAME DISEASE?
by: M. Jagurinoski, et al.
Published: (2022-06-01)

Targeting MTHFD2 in acute myeloid leukemia
by: Pikman, Yana, et al.
Published: (2022)

Targeting MTHFD2 in acute myeloid leukemia
by: Pikman, Yana, et al.
Published: (2017)

Targeted Therapy Development in Acute Myeloid Leukemia
by: Tulasigeri M. Totiger, et al.
Published: (2023-02-01)

PB1842: EARLY DEATH IN NEWLY DIAGNOSED ADULT ACUTE MYELOID LEUKEMIA
by: N. Siala, et al.
Published: (2022-06-01)

PB1799: KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
by: E. Zerkalenkova, et al.
Published: (2022-06-01)

PB1807: THE SIGNIFICANCE OF MOLECULAR RISK FACTORS IN ACUTE MYELOID LEUKEMIA
by: Alla Gordienko, et al.
Published: (2023-08-01)

PB1804: SLC7A11 IS A POTENTIAL THERAPEUTIC TARGET IN ACUTE MYELOID LEUKEMIA
by: Jiazheng LI, et al.
Published: (2023-08-01)